

REMARKS

Following entry of the foregoing amendments, claims 20 to 26 and 30 to 42 will be pending in this patent application. Claims 21 and 26 have been amended, and claims 1 to 19 have been canceled, herein, without prejudice. Support for the amendments is found throughout the specification as originally filed, and the amendments therefore do not introduce new matter into the application.

Applicants respectfully request reconsideration of the objections of record in view of the foregoing amendments and the following remarks.

Claim Objections

Claim 21 has been objected to for reciting “**an** amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5,” and claim 26 has been objected to for reciting “**an** amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5,” instead of reciting “**the**” amino acid sequence of one of the indicated sequence identification numbers. Without conceding the correctness of this objection, and to advance prosecution, claims 21 and 26 have been amended to replace “an” with “the,” thereby obviating this objection.¹ Applicants accordingly, respectfully, request withdrawal thereof.

Alleged Possible Lack of Enablement

Previously withdrawn method claims 1 to 19 were rejoined under *In re Ochiai*, and the Office indicates in the advisory action dated April 7, 2011 that further consideration and/or a new search would be required to determine whether these claims meet the enablement requirement. A request for continued examination would therefore be required to pursue further prosecution of these claims. Without conceding that the subject matter of claims 1 to 19 does not

¹ In the advisory action dated April 7, 2011, the Office also indicated that claims 21 and 26 should recite “selected from the group consisting of” after the word “sequence.” Examiner Audet indicated via telephone to applicants’ undersigned representative on May 13, 2011, however, that this amendment would not be necessary, and recitation of “the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5” is acceptable and not objectionable.

DOCKET NO.: NIHA-0383
Application No.: 10/588,884
Office Action Dated: January 24, 2011

PATENT

fulfill the enablement requirement, to advance prosecution of this application, claims 1 to 19 have been canceled herein, without prejudice.

Conclusion

Applicants believe that the foregoing constitutes a complete and full response to the official action of record. An early and favorable action is therefore respectfully requested.

Date: May 23, 2011

Respectfully submitted,

/Jane E. Inglese/

Jane E. Inglese, Ph.D.
Registration No. 48,444

Woodcock Washburn LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439